In a trial of combined hormone treatment and cytotoxic chemotherapy 464 patients with advanced breast cancer were randomly allocated to either concurrent or sequential treatment. Cytotoxic drugs were given only if the antitumour activity of the hormone treatment was inadequate. Hormone treatment consisted of oophorectomy for premenopausal and tamoxifen administration for postmenopausal patients. Length of survival was better, though not significantly, in premenopausal patients (p= 0-29) treated concurrently and in postmenopausal women (p=0 17) treated sequentially; the difference was highly significant (p-0 003) only for postmenopausal women in the low-risk -category. The
Introduction
Breast cancer tissue is thought to be composed of at least two different cellular types, one which is responsive to hormone treatment and one which is sensitive to cytotoxic drugs.' A combination of both treatments should therefore improve the results of treatment of advanced breast cancer, particularly as no appreciable progress seems to occur when only one of the currently available treatments is used. The first trials of the efficacy of combining hormone and cytotoxic drug treatment yielded conflicting results.2 S Nevertheless there is a widespread tendency to treat many patients with a combination of both treatments simultaneously. In our randomised study we compared this approach with more conservative management, in which chemotherapy was given only if the antitumour activity of hormone treatment was insufficient.
Patients and methods

SELECTION
Between September 1975 and December 1980, 464 patients with a measurable advanced breast cancer who had not previously received chemotherapy or hormone treatment were entered into the trial.
Patients with brain metastases and impaired renal or hepatic function were excluded. Osteoblastic boney metastases and malignant effusions were not accepted as measurable lesions. Fifty-eight patients had to be excluded from the present analysis, because in seven tumour size was difficult to evaluate, in 42 there was a major protocol violation, and in nine death occurred within four weeks of starting treatment. The patients were stratified according to menopausal status and risk category, based on retrospective analysis of two of our previous studies.5
Low-risk category-This was based on the following features: (a) I JANUARY 1983 5 contralateral nodal metastases only, with a free interval between mastectomy and diagnosis of the first metastasis of at least two years; (b) boney metastases only, irrespective of the free interval; and (c) no more than two of the following: (i) lung or liver metastases (not both) with a free interval of at least four years; (ii) an isolated boney metastasis with a free interval of at least two years; (iii) skin metastases or an ipsilateral malignant pleural effusion with a free interval of at least two years or both; and (iv) ipsilateral nodal metastases and a free interval of at least two years. High-risk category-This included all the remaining patients. Hormone receptors were not considered, since their determination was generally possible only towards the end of the accrual period.
RANDOMISATION
After stratification patients were randomised to treatment groups A (concurrent hormone treatment and chemotherapy) or B (sequential hormone treatment and chemotherapy). Premenopausal women underwent oophorectomy and postmenopausal patients received 20 mg tamoxifen daily. In group A the patients received chemotherapy concurrently; in group B cytotoxic drugs were given only after 6-8 weeks of hormone treatment except in cases of confirmed tumour regression, in which chemotherapy was begun later and only after the tumour had been reassessed. At the time of randomisation to the two treatment groups, patients were also randomly allocated to three different regimens representing minimal, conventional, and intensive cytotoxic treatment. The details of these three regimens and the results of the comparison among the three groups, showing significant differences in response rates but similar survival curves, have been published elsewhere. The survival period and the time to progression of the disease were calculated from entry into the study. Actuarial curves were based on the method described by Kaplan and Meier.7 The statistical comparison among actuarial curves was carried out using the log-rank test, the Mantel-Cox test, and the generalised Wilcoxon test.8 In the case of differences among the statistical tests the least significant result was recorded.
Results
Of The risk category, the free interval, and the localisation and number of metastatic sites had a statistically significant effect on survival. A multifactorial analysis correlating these prognostic factors with the two different therapeutic approaches failed to show statistically significant differences in most instances. The survival period tended to be consistently longer with concurrent chemotherapy in patients with a more aggressive disease (that is, a shorter free interval and less favourable pattern of metastatic lesions). Patients with a less aggressive disease, however (that is, longer free interval and more favourable metastatic sites) showed a similar not statistically significant tendency to live longer with sequential chemotherapy. Only in two subgroups was there a statistically significant difference in survival. Patients in the age group 40-45 years had a median survival time of 43 1 months in group A and 18 months in group B (p < 0 05). Among the 80 post- aggressive chemotherapeutic regimens are presently being explored to improve these results.' 0 -12 At the same time, however, the overall impact of the use of multiple cytotoxic agents on the survival of most patients with advanced breast cancer has been questioned.'3 14 Our results may partially support this assumption. In the analysis of the effect of cytotoxic drugs in our trial the statistically significant differences in the response rate with various cytotoxic regimens could only be marginally translated to the different survival curves.6 Differences in survival according to therapeutic result (fig 3) are of limited value in assessing the effect of treatment on survival. In fact some of the patients who responded might have survived almost as long without treatment, whereas in some patients who did not respond the treatment may have actually shortened their survival. At present probably only some subgroups of patients with advanced breast cancer will have their life significantly prolonged by chemotherapy.
Our trial is the third to assess the effects of simultaneous compared with sequential use of combined hormone treatment and chemotherapy in premenopausal patients with metastatic breast cancer. To our knowledge, however, such a study has so far not been carried out in postmenopausal women. Our results for premenopausal women confirm the findings of the two previous reports. '5 16 Overall, patients receiving cytotoxic drugs immediately after oophorectomy tended to live longer than patients for whom the onset of cytotoxic treatment was delayed; the difference, however, was not statistically significant. In all three trials a clear definition of the subgroups of premenopausal patients who would benefit from the concurrent use of both treatments has possibly been hampered by the difficultv in finding a sufficient number of suitable patients. Furthermore, the very similar survival data in our study for low-risk and highrisk cases brings into question the usefulness of this stratification in premenopausal women. Whereas in the two previous studies chemotherapy was given in cases in which the tumour had progressed after hormone treatment, in our trial cytotoxic drugs were also given to patients who showed no change with hormone treatment. The possibility that with a less prudent study design our differences in survival would have been more pronounced cannot be dismissed.
Among the postmenopausal patients women receiving cytotoxic drugs only after treatment with tamoxifen had failed to produce or maintain measurable tumour regression survived consistently longer, even if not statistically significantly, than those receving tamoxifen and cytotoxic drugs simultaneously.
For patients with a less aggressive tumour, the low-risk group, the difference was highly significant (fig 3) . Interestingly, the median survival was very similar with both treatments among postmenopausal patients in the high-risk category (table III) . In the analysis of the different subgroups of postmenopausal patients according to their prognostic factors (that is, free interval and number and localisation of metastatic sites) we were unable to define a group which could have benefited from concurrent treatment with tamoxifen and cytotoxic drugs. Our data suggest that postmenopausal women with metastatic breast cancer should probably be primarily treated by a carefully monitored trial of hormone treatment and not initially with cytotoxic drugs, which in older patients can have unpleasant side effects. It is, perhaps, noteworthy that among the postmenopausal women the longest median survival was recorded for patients treated sequentially with the least intensive regimen of cytotoxic drugs.6 In our previous trial only a subgroup of patients receiving simultaneously cytotoxic drugs and oestrogens lived longer than patients treated with cytotoxic drugs alone.2 In a more recent and careful study of simultaneous treatment with cytoxan, methotrexate, fluorouracil, and tamoxifen in postmenopausal women compared with cytoxan, methotrexate, and fluorouracil alone, patients treated with the three drugs alone subsequently received the four-drug combination after primary or secondary failure of the combination without tamoxifen.17 Even if initial treatment with the four-drug combination produced a significantly higher response rate, survival was longer for patients treated initially with the three-drug combination and later by the same regimen supplemented with tamoxifen. This emphasises again the poor correlation between differences in the response rate to primary treatment and eventual survival of patients with breast cancer and supports, as do our present findings, a sequential therapeutic approach as superior in postmenopausal patients. Since subsequent remissions are possible with later hormone and cytotoxic regimens, more detailed clinical studies are necessary to define the most appropriate sequence of the various treatments available for postmenopausal patients with advanced breast cancer.
